Navigation Links
Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

-- Product Expansion

- Launched two major new products: the Thermogard XP (TM) Temperature

Management system, which is designed to provide an enhanced level of

therapeutic cooling power; and the Quattro (TM) catheter, a

four-balloon heat exchange catheter that provides increased surface

area and power with triple lumen central venous access.

-- Clinical Validation

- Alsius' products were featured in over 85 articles, abstracts and

presentations in peer-reviewed journals or medical meetings around

the world, including the Congress of Neurological Surgeons, the

American College of Surgeons, European Burns Association, the

International Hypothermia Symposium, and the Neurocritical Care

Society.

- The peer-reviewed journal, Critical Care, published a study in

August comparing different cooling methods and concluded that Alsius

intravascular cooling demonstrated the fastest cooling rates and was

the most reliable for maintaining stable body temperature. The study

evaluated Alsius intravascular temperature management, conventional

(cold intravenous fluids and/or cold packs), water and air

circulating blankets and water circulating gel-coated pads.

Conference Call Details

Alsius will host a conference call and webcast on March 13, 2008 at 4:30 p.m. Eastern Time. To participate in the teleconference, participants in the U.S. and Canada may call 877-440-5791 while international callers should dial 719-325-4879. No password is required for the live teleconference. To access the webcast, please go to the Investor Relations page on our website http://www.alsius.com.

A telephone replay of the conference call will be available 90 minutes after the call concludes on March 13 through March 31, 2008.
'/>"/>

SOURCE Alsius Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
2. Alsius Corporation Announces Program for Early Exercise of Warrants
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... ... , ... Illinois Health & Science (IHS) has completed the purchase of IBA ... of IBAM NA’s cyclotron sites and research and development facilities. , “We ... well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... with accountability for overall performance of the company’s Medicare and Federal Employee Programs ... Cambia’s strategy to deliver better health for members. In this role, Scott is ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Institute of Medical Sciences (KIMS), a leading hospital here, ... accreditation that will// help it attract patients from abroad. ... the Australian Council for Health Care Standards International (ACHSI), ... extensive, week-long survey of KIMS facilities. KIMS has become ...
... from chronic asthma do not get proper treatment and ... ,Specialists at the Johns Hopkins Children’s Center and elsewhere ... the researchers say, because preventive therapy failure leads to ... strikes and to more complications and increased risk of ...
... tiny heating device that can be inserted inside the lungs ... or nose can help treat asthma, researchers conducting its// trial ... system in which the airways constrict making it hard to ... ,Though asthma can't be cured, it can be managed with ...
... senior and well-known scientist of America’s premier medical agency ... criminal conflict of interests.// ,Dr Trey Sutherland ... drug company as consulting fees as well as providing ... is said to have received $285,000 in payment for ...
... the anti-craving drug, Naltrexone may lessen cessation-related weight gain ... quit smoking appear //to benefit more than men. As ... on gender differences in nicotine addiction and in treatment. ... of the University of Chicago have added a drug ...
... hair-growth drug finasteride, taken by millions of balding men, ... test,// the standard screening test for prostate cancer, a ... men ranging in age from 40 to 60 years ... The Lancet and is scheduled to be published after ...
Cached Medicine News:Health News:Medication Not Available On Time To Inner-city Children 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
... is synthesized by the parathyroid glands ... decreased extracellular calcium concentrations. PTH prevents ... decreasing calcium excretion by the kidney. ... PTH is rapidly degraded into 4 ...
... is produced in the adrenal cortex and, ... DHEA serves as a precursor in testosterone ... androgenic activity, estimated at ~10% that of ... and in adult women, DHEA is an ...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
Medicine Products: